Justin Zelin
Stock Analyst at BTIG
(1.35)
# 3,211
Out of 4,829 analysts
37
Total ratings
20.59%
Success rate
-3.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Initiates: Buy | $6 | $2.33 | +157.51% | 1 | Jan 10, 2025 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $42 | $19.16 | +119.21% | 1 | Dec 13, 2024 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | n/a | $0.19 | - | 2 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $55 → $62 | $18.44 | +236.23% | 2 | Jul 9, 2024 | |
| JSPR Jasper Therapeutics | Initiates: Buy | $90 | $4.86 | +1,751.85% | 1 | Jul 8, 2024 | |
| TCRX TScan Therapeutics | Initiates: Buy | $12 | $1.33 | +805.66% | 1 | May 16, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Neutral | n/a | $0.09 | - | 2 | May 6, 2024 | |
| VKTX Viking Therapeutics | Maintains: Buy | $100 → $125 | $28.43 | +339.68% | 4 | Mar 26, 2024 | |
| VSTM Verastem | Assumes: Buy | $27 | $7.07 | +281.90% | 1 | Nov 21, 2023 | |
| MBIO Mustang Bio | Maintains: Buy | $1,000 → $800 | $1.15 | +69,525.76% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $29.27 | +210.95% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $0.68 | +1,369.51% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $0.76 | +2,001.94% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $8.22 | +350.12% | 2 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $35 | $11.20 | +212.50% | 1 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $33.13 | +171.66% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $6.18 | +402.02% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $67.49 | -77.03% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.09 | - | 3 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $1.89 | +429.63% | 3 | Nov 16, 2022 |
ImmunityBio
Jan 10, 2025
Initiates: Buy
Price Target: $6
Current: $2.33
Upside: +157.51%
Enliven Therapeutics
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $19.16
Upside: +119.21%
Carisma Therapeutics
Dec 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.19
Upside: -
IDEAYA Biosciences
Jul 9, 2024
Maintains: Buy
Price Target: $55 → $62
Current: $18.44
Upside: +236.23%
Jasper Therapeutics
Jul 8, 2024
Initiates: Buy
Price Target: $90
Current: $4.86
Upside: +1,751.85%
TScan Therapeutics
May 16, 2024
Initiates: Buy
Price Target: $12
Current: $1.33
Upside: +805.66%
Lyra Therapeutics
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.09
Upside: -
Viking Therapeutics
Mar 26, 2024
Maintains: Buy
Price Target: $100 → $125
Current: $28.43
Upside: +339.68%
Verastem
Nov 21, 2023
Assumes: Buy
Price Target: $27
Current: $7.07
Upside: +281.90%
Mustang Bio
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $1.15
Upside: +69,525.76%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $29.27
Upside: +210.95%
Aug 10, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $0.68
Upside: +1,369.51%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $0.76
Upside: +2,001.94%
Jul 3, 2023
Maintains: Buy
Price Target: $30 → $37
Current: $8.22
Upside: +350.12%
Jun 26, 2023
Maintains: Buy
Price Target: $34 → $35
Current: $11.20
Upside: +212.50%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $33.13
Upside: +171.66%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $6.18
Upside: +402.02%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $67.49
Upside: -77.03%
Dec 6, 2022
Downgrades: Neutral
Price Target: n/a
Current: $2.09
Upside: -
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $1.89
Upside: +429.63%